ROCKET PHARMACEUTALS, INC. director David P. Southwell reported equity awards, not open-market trades. He received 22,862 restricted stock units (RSUs) that convert one-for-one into common stock and will vest in full on June 18, 2027. He was also granted a stock option for 64,860 shares of common stock at an exercise price of $3.35 per share, which becomes fully vested and exercisable on June 18, 2027 and expires on June 18, 2036. Following these awards, he directly owns 54,522 shares of common stock and indirectly holds 113,124 shares through The David P. Southwell Irrevocable Trust dated April 14, 2024.
Rocket Pharmaceuticals director Carsten Boess reported stock-based awards that increase his equity stake in the company. He received 22,862 restricted stock units that convert into common stock on a one-for-one basis and will vest in full on June 18, 2027. He also received options covering 64,860 shares of common stock at an exercise price of $3.35 per share, which will become fully vested and exercisable on June 18, 2027. Following the grant, his direct holdings of common stock total 52,862 shares, with the new option award providing additional potential future ownership.
Rocket Pharmaceuticals, Inc. announced leadership changes in its finance organization. John Militello, VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, has resigned effective July 7, 2026 to pursue other opportunities. Joseph Manhede, currently Associate Vice President, Corporate Controller, will become Principal Accounting Officer effective July 8, 2026.
Manhede, age 48, joined Rocket in April 2026 and previously held senior finance roles at Outlook Therapeutics, Amneal Pharmaceuticals, Unilife Corporation and Celator Pharmaceuticals after starting his career at Deloitte. He is a CPA with an MBA from Holy Family University. The company states there are no new compensatory arrangements or related-party transactions tied to his designation.
Rocket Pharmaceuticals has completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company for $180 million in gross, non-dilutive proceeds. The voucher was granted following FDA approval of KRESLADI, Rocket’s gene therapy for severe leukocyte adhesion deficiency-I.
Rocket previously reported cash, cash equivalents and investments of $144.4 million as of March 31, 2026. Pro forma for the voucher sale, this increases to about $322.6 million, which the company expects will fund operations into the second quarter of 2028.
ROCKET PHARMACEUTICALS, INC. reported that officer John Militello participated in an option exchange program on May 26, 2026. The company cancelled multiple out-of-the-money stock options previously held by him and took them back as a disposition to the issuer.
In exchange, Militello received several new stock options to buy common stock at an exercise price of $3.00 per share, which footnotes state was the closing price of the common stock on that date. The new grants cover different amounts and maturities, including rights to purchase 9,091 shares expiring on February 16, 2034 and 51,509 shares expiring on May 26, 2031, all subject to continued employment-based vesting.
The cancelled options included higher-strike awards such as 24,545 options at an exercise price of $30.01 and 49,798 options at $20.04, among other tranches with exercise prices up to $62.32 per share.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported an option exercise and related share sale in Common Stock. He exercised stock options for 76,490 shares at $1.691 per share and sold 55,684 shares at a weighted average price of $3.086 per share.
According to the disclosure, the sale was made to pay the option exercise price and cover certain taxes tied to the exercise. After these transactions, Shah directly holds 1,061,724 shares of Common Stock, and additional shares are held indirectly through a trust and by his spouse. Direct holdings include Restricted Stock Units that convert to common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a small share sale primarily tied to equity compensation. On common stock, he sold 2,409 shares in an open-market transaction at about $3.014 per share to pay tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
After this transaction, Shah directly holds 1,040,918 shares of common stock, and also reports indirect holdings of 198,341 shares through the Gaurav D. Shah Irrevocable Trust and 207,897 shares held by his spouse. Footnotes note that his holdings include RSUs that convert into common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. General Counsel Martin Wilson reported a small open-market sale of company common stock. He sold 662 shares on May 19, 2026 at an average price of $3.014 per share. Footnotes state the sale was made to cover tax withholding obligations related to vesting Restricted Stock Units that convert into common stock on a one-for-one basis. After this transaction, he continues to hold 677,977 shares of common stock, indicating the sale represents a very small portion of his overall position.
ROCKET PHARMACEUTICALS, INC. officer John Militello reported selling 384 shares of common stock at $3.014 per share on May 19, 2026. According to the footnotes, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis.
After this transaction, Militello directly holds 89,780 shares of common stock. The filing characterizes the trade as an open-market sale but clarifies that its purpose was to cover taxes related to equity compensation rather than a discretionary portfolio adjustment.
Rocket Pharmaceuticals files a Form 144 to sell 55,684 shares. The filing lists an intended sale of 55,684 shares of Common Stock via an option granted on 04/12/2017, with the sale dated 05/21/2026 for cash. The filing also discloses recent transfers: 2,728 shares sold on 05/13/2026 for $9,836.08 and 2,409 shares sold on 05/19/2026 for $7,261.69.